Liver transplantation is often the last and best hope for patients whose livers have failed, but the surgery is only the beginning of a long immunological negotiation. Even under powerful immunosuppressive drugs, between 15 and 30 percent of recipients experience acute rejection, a sudden attack by the immune system on the newly implanted organ. Clinicians currently detect rejection only after it has begun, relying on liver biopsies that are invasive, uncomfortable, and impossible to perform continuously. A new study published in Genome Medicine by researchers at Yonsei University College of Medicine in Seoul suggests that the seeds of rejection may be visible in a simple blood sample taken before the transplant even happens, offering a potential route to earlier, non-invasive risk prediction.
The research team, led by Su-Hyeon Lee and Deok-Gie Kim, with corresponding authors Byungjin Hwang and Dong Jin Joo, took an unusually rigorous approach to a difficult clinical problem. They recruited 20 liver transplant recipients and collected paired samples of peripheral blood mononuclear cells, the circulating immune cells that include lymphocytes and monocytes, both before surgery and after transplantation. Ten of these patients went on to develop acute rejection and ten did not. Crucially, the two groups were matched for a battery of clinical variables that could otherwise confound the analysis, including age, sex, hepatocellular carcinoma status, autoimmune disease status, ABO blood group compatibility, and donor age. By controlling for these factors, the investigators could be more confident that the immunological differences they found were genuinely linked to rejection rather than to incidental patient characteristics.
Technically, the study is a tour de force of single-cell multi-omics. Rather than averaging gene expression across bulk tissue, the team used single-cell RNA sequencing to profile 88,940 high-quality individual cells, preserving the identity and state of each immune cell. They paired this transcriptomic readout with T cell receptor sequencing, which reads the unique genetic rearrangements that give each T cell its antigen-specific receptor. This combination allowed them to track not only which cell types were present and what genes they were expressing, but also how T cell clones expanded, contracted, and diversified over time. On top of the sequencing data, the researchers layered computational analyses of gene regulatory networks and intercellular communication, reconstructing the signaling conversations between immune cell populations that precede and accompany rejection.
The most striking finding is that the immune systems of future rejecters looked different before transplantation. Patients who later developed acute rejection already showed a distinct pre-transplant immune state compared with those who tolerated their new livers. Natural killer cells in the rejection group displayed an inflammatory activation profile with enhanced responsiveness to interferon, a family of signaling proteins central to antiviral and immune defense responses. Monocytes, the innate immune cells that patrol the blood and seed tissues, showed altered composition and transcriptional programs dominated by interferon-associated signatures. Together, these observations suggest a systemic, low-grade inflammatory readiness in the circulation of patients whose immune systems would later turn against the graft.
The adaptive immune side of the story was equally revealing. Before surgery, recipients who went on to reject showed a skewing of their CD8 T cell compartment toward effector memory states. Effector memory CD8 T cells are the rapid-response soldiers of the immune system: they circulate in the blood and peripheral tissues, and when they encounter their target antigen they can immediately deploy cytotoxic machinery without the delay required for naive T cells to differentiate. A pre-existing bias toward this compartment means the patient carries a standing army of cytotoxic cells primed for fast action, a configuration that could plausibly accelerate an attack on donor tissue once transplantation delivers a flood of foreign antigens.
After transplantation, the divergence between the two groups did not close; it widened in specific ways. Despite receiving standard immunosuppression, rejection patients maintained heightened overall immune activity. The team observed an expansion of KIR-expressing effector memory CD8 T cell populations in these patients. KIR, or killer cell immunoglobulin-like receptors, are molecules classically associated with natural killer cells that tune their reactivity to self, but their expression on CD8 T cells marks a subset with distinctive effector properties. The rejection group also showed increased expression of IRF1, a transcription factor that sits downstream of interferon signaling and orchestrates inflammatory gene programs in CD8 T cells. In other words, the post-transplant immune landscape of rejecters retained an activated, interferon-driven character that immunosuppression failed to fully extinguish.
To move from descriptive biology toward clinical utility, the researchers searched for genes whose expression reliably distinguished rejecting from non-rejecting patients across multiple time points. They identified 15 robust acute rejection-associated genes that were consistently detected before and after transplantation, and then validated a subset of these genes in liver biopsy tissue from the patients. This cross-validation is important: it links the circulating blood signature to the actual immunological battleground inside the graft, supporting the idea that a peripheral blood test could serve as a proxy for processes occurring in the transplanted liver. A blood-based biomarker panel built on such genes could, in principle, flag high-risk patients before rejection becomes clinically manifest, allowing clinicians to intensify monitoring or tailor immunosuppressive regimens without resorting to repeated biopsies.
The implications reach beyond liver transplantation. Acute cellular rejection is fundamentally a problem of immune recognition and memory, and the Yonsei study demonstrates that the relevant information is encoded in the composition and activation state of circulating immune cells. The finding that pre-transplant immune states predispose recipients to rejection challenges the traditional view of rejection as a purely post-transplant event driven by donor-recipient mismatch alone. Instead, the recipient’s baseline immune configuration, shaped by their disease history, viral exposures, and inflammatory milieu, appears to set the stage for how the immune system will respond to the graft. This reframing aligns with a broader trend in transplant immunology toward precision medicine, in which immunological risk stratification replaces one-size-fits-all immunosuppression.
There are, of course, important caveats. The study involved 20 carefully matched patients, a sample size appropriate for discovery but too small to support immediate clinical deployment of a diagnostic test. The 15-gene signature and the cellular features identified will need validation in larger, independent, and ideally multi-center cohorts before they can inform treatment decisions. It also remains to be seen whether the signatures generalize across different donor types, immunosuppressive protocols, and causes of liver failure. Nonetheless, the methodological framework, integrating single-cell transcriptomics, T cell receptor repertoire tracking, regulatory network inference, and tissue validation, provides a template that other transplant programs can adopt to build the evidence base needed for clinical translation.
For patients awaiting a liver, the promise is tangible: a pre-operative blood draw that reveals whether their immune system is primed for conflict, and post-operative monitoring that catches rejection in its earliest molecular stages rather than after tissue damage has occurred. For the field of transplant immunology, the study adds a detailed cellular and molecular atlas of how rejection unfolds in the human circulation, from interferon-primed natural killer cells and interferon-signature monocytes to KIR-expressing effector memory CD8 T cells and IRF1-driven inflammatory programs. As single-cell sequencing becomes faster and cheaper, the vision of routine immune profiling before and after organ transplantation moves closer to reality, and with it the possibility of preventing rejection rather than merely treating it.
Subject of Research: Single-cell RNA sequencing and T cell receptor repertoire analysis of immune signatures associated with acute liver allograft rejection
Article Title: Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection
Article References: Lee, S.-H., Kim, D.-G., Cho, Y., Min, E.-K., Lee, J. G., Kim, M. S., Park, S., Hwang, B., & Joo, D. J. (2026). Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection. Genome Medicine. https://doi.org/10.1186/s13073-026-01753-4
Image Credits: AI Generated
DOI: 10.1186/s13073-026-01753-4
Keywords: liver transplantation, acute rejection, single-cell RNA sequencing, T cell receptor repertoire, CD8 T cells, natural killer cells, monocytes, interferon signaling, IRF1, biomarkers, immunosuppression, Genome Medicine
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (October 1, 2026). Blood Clues Before Surgery Predict Who Will Reject a New Liver. Scienmag. https://scienmag.com/blood-clues-before-surgery-predict-who-will-reject-a-new-liver/
Ophelia Keating. “Blood Clues Before Surgery Predict Who Will Reject a New Liver.” Scienmag, 1 October 2026, https://scienmag.com/blood-clues-before-surgery-predict-who-will-reject-a-new-liver/. Accessed 1 October 2026.
Ophelia Keating. “Blood Clues Before Surgery Predict Who Will Reject a New Liver.” Scienmag. October 1, 2026. https://scienmag.com/blood-clues-before-surgery-predict-who-will-reject-a-new-liver/
Copy citation Download RIS
Tags: acute rejectionBiomarkersblood sample analysis for transplant risk assessmentCD8+ T cellsearly detection of liver graft rejectionGenome Medicinegenome-based prediction of transplant rejectionimmune cell profiling in liver transplant patientsimmune response markers in liver transplantationimmunological markers for transplant outcomesimmunosuppressioninterferon signalingIRF1liver transplantationliver transplantation rejection predictionmonitoring transplant rejection without invasive biopsiesmonocytesnatural killer cellsnon-invasive methods for detecting transplant rejectionperipheral blood mononuclear cells in transplant monitoringpredictive analytics in transplant immunologypreoperative blood biomarkers for organ rejectionSingle-Cell RNA SequencingT-cell receptor repertoire
